{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:49:09Z","timestamp":1789004949570,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ctrv.2025.102889","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:05:50Z","timestamp":1737763550000},"page":"102889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Diagnosis and management of bispecific T cell\u2013engaging antibody toxicity: A primer for emergency physicians"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-4974","authenticated-orcid":false,"given":"Monica K","family":"Wattana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-8461","authenticated-orcid":false,"given":"Aiham","family":"Qdaisat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Levavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Rohs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demis N.","family":"Lipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctrv.2025.102889_b0005","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102889_b0010","doi-asserted-by":"crossref","unstructured":"Noori M, Yazdanpanah N, Rezaei N. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int. 2023;23(1)doi:10.1186\/s12935-023-03045-y.","DOI":"10.1186\/s12935-023-03045-y"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102889_b0015","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102889_b0020","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.ajem.2020.03.013","article-title":"Oncologic emergencies in the emergency medicine residency curriculum: a national survey","volume":"38","author":"Rajha","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102889_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/aet2.10987","article-title":"Current gaps in emergency medicine core content education for oncologic emergencies: a targeted needs assessment","volume":"8","author":"Wattana","year":"2024","journal-title":"AEM Educ Train"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102889_b0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jemermed.2023.02.016","article-title":"The 2022 model of the clinical practice of emergency medicine","volume":"64","author":"Beeson","year":"2023","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ctrv.2025.102889_b0035","unstructured":"US Food and Drug Administration. Bispecific Antibodies: An Area of Research and Clinical Applications. 2021 May. Accessed June 24, 2024. https:\/\/www.fda.gov\/drugs\/spotlight-cder-science\/bispecific-antibodies-area-research-and-clinical-applications."},{"key":"10.1016\/j.ctrv.2025.102889_b0040","article-title":"Bispecific antibody toxicity","author":"Chennapragada","year":"2024","journal-title":"StatPearls"},{"key":"10.1016\/j.ctrv.2025.102889_b0045","doi-asserted-by":"crossref","unstructured":"Leclercq G, Servera LA, Danilin S, et al. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology. 2022;11(1)doi:10.1080\/2162402x.2022.2039432.","DOI":"10.1080\/2162402X.2022.2039432"},{"issue":"10396","key":"10.1016\/j.ctrv.2025.102889_b0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102889_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.841117","article-title":"Cytokine release syndrome and associated acute toxicities in pediatric patients undergoing immune effector cell therapy or hematopoietic cell transplantation","volume":"12","author":"Baumeister","year":"2022","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102889_b0060","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102889_b0065","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102889_b0070","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102889_b0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102889_b0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102889_b0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102889_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/BLCTT.S223894","article-title":"Evaluating blinatumomab for the treatment of relapsed\/refractory ALL: design, development, and place in therapy","volume":"10","author":"Sigmund","year":"2020","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.ctrv.2025.102889_b0095","doi-asserted-by":"crossref","unstructured":"Chaftari P, Qdaisat A, Chaftari AM, et al. Prognostic Value of Procalcitonin, C-Reactive Protein, and Lactate Levels in Emergency Evaluation of Cancer Patients with Suspected Infection. Cancers (Basel). Aug 13 2021;13(16)doi:10.3390\/cancers13164087.","DOI":"10.3390\/cancers13164087"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102889_b0100","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1002\/cam4.5665","article-title":"Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients","volume":"12","author":"Powell","year":"2023","journal-title":"Cancer Med"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102889_b0105","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/blood-2018-99-120065","article-title":"Procalcitonin as a potential biomarker for differentiating bacterial infectious fevers from cytokine release syndrome","volume":"132","author":"Maakaron","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102889_b0110","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. Feb 19 2014;6(224):224ra25. doi:10.1126\/scitranslmed.3008226.","DOI":"10.1126\/scitranslmed.3008226"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102889_b0115","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102889_b0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102889_b0125","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2025.102889_b0130","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102889_b0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102889_b0140","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102889_b0145","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102889_b0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102889_b0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102889_b0160","doi-asserted-by":"crossref","unstructured":"Urbino I, Lengline E, Valade S, et al. Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia. Crit Care. Jan 5 2024;28(1):14. doi:10.1186\/s13054-023-04787-x.","DOI":"10.1186\/s13054-023-04787-x"},{"key":"10.1016\/j.ctrv.2025.102889_b0165","doi-asserted-by":"crossref","unstructured":"Afrough A, Abraham PR, Turer L, et al. Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematol. May 8 2024:1-15. doi:10.1159\/000539134.","DOI":"10.1159\/000539134"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102889_b0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102889_b0175","doi-asserted-by":"crossref","unstructured":"Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med. Apr 29 2021;11(5)doi:10.3390\/jpm11050355.","DOI":"10.3390\/jpm11050355"},{"key":"10.1016\/j.ctrv.2025.102889_b0180","doi-asserted-by":"crossref","unstructured":"Rubin DB, Al Jarrah A, Li K, et al. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. JAMA Neurology. 2020;77(12)doi:10.1001\/jamaneurol.2020.2703.","DOI":"10.1001\/jamaneurol.2020.2703"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102889_b0185","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1080\/10428194.2022.2074990","article-title":"Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy","volume":"63","author":"Lapidus","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2025.102889_b0190","doi-asserted-by":"crossref","unstructured":"Rees JH. Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, eds. The EBMT\/EHA CAR-T Cell Handbook. 2022:141-5.","DOI":"10.1007\/978-3-030-94353-0_27"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102889_b0195","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.ctrv.2025.102889_b0200","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102889_b0205","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2025.102889_b0210","doi-asserted-by":"crossref","unstructured":"Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. Aug 1 2023;13(1):116. doi:10.1038\/s41408-023-00879-7.","DOI":"10.1038\/s41408-023-00879-7"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102889_b0215","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102889_b0220","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102889_b0225","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm","volume":"35","author":"Martinelli","year":"2017","journal-title":"Multicenter Study J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102889_b0230","unstructured":"Center for Drug Evaluation and Research. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. U.S. Food and Drug Administration. Accessed Accessed July 1, 2024. , https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer."},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102889_b0235","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2023-189648","volume":"142","author":"Luger","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102889_b0240","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102889_b0245","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2025.102889_b0250","unstructured":"Amgen. IMDELLTRA (tarlatamab-dlle) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761344s000lbl.pdf. Revised May 2024. Accessed June 29, 2024."},{"issue":"3","key":"10.1016\/j.ctrv.2025.102889_b0255","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.clml.2022.12.009","article-title":"Efficacy and safety of blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a systemic review and meta-analysis","volume":"23","author":"Liu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102889_b0260","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1182\/blood-2022-170579","article-title":"Incidence of central nervous system toxicity and cytokine release syndrome in leukemia patients treated with blinatumomab","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102889_b0265","doi-asserted-by":"crossref","unstructured":"Aldoss I, Khaled SK, Budde E, Stein AS. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. Curr Oncol Rep. Jan 21 2019;21(1):4. doi:10.1007\/s11912-019-0753-y.","DOI":"10.1007\/s11912-019-0753-y"},{"key":"10.1016\/j.ctrv.2025.102889_b0270","unstructured":"FDA APPROVES BLINCYTO\u00ae (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE | Amgen Inc. Amgen Inc. Published 2021. https:\/\/investors.amgen.com\/news-releases\/news-release-details\/fda-approves-blincytor-blinatumomab-cd19-positive-philadelphia. Accessed July 5, 2024."},{"issue":"3","key":"10.1016\/j.ctrv.2025.102889_b0275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102889_b0280","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1097\/MJT.0000000000001009","article-title":"Blinatumomab-associated neurological adverse events","volume":"27","author":"Ahmed","year":"2020","journal-title":"Am J Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102889_b0285","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann Hematol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102889_b0290","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102889_b0295","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5045\/br.2022.2021163","article-title":"Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk","volume":"57","author":"Wo","year":"2022","journal-title":"Blood Res"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102889_b0300","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102889_b0305","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2025.102889_b0310","doi-asserted-by":"crossref","unstructured":"Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. Mar 27 2019;11(485)doi:10.1126\/scitranslmed.aau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"issue":"24","key":"10.1016\/j.ctrv.2025.102889_b0315","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2025.102889_b0320","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2025.102889_b0325","doi-asserted-by":"crossref","unstructured":"Rasche L, Schinke C, Chari A, et al. P892: Analysis of Infections and Parameters of Humoral Immunity in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (Rrmm) Treated with Talquetamab (Tal) Monotherapy in Monumental-1. HemaSphere. 2023;7(S3)doi:10.1097\/01.HS9.0000970472.64690.4e.","DOI":"10.1097\/01.HS9.0000970472.64690.4e"},{"key":"10.1016\/j.ctrv.2025.102889_b0330","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, van de Donk N, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. Feb 2 2024;14(1):24. doi:10.1038\/s41408-023-00966-9.","DOI":"10.1038\/s41408-023-00966-9"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102889_b0335","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102889_b0340","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102889_b0345","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23524","article-title":"Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era","volume":"88","author":"Nagle","year":"2013","journal-title":"Am J Hematol"},{"issue":"10306","key":"10.1016\/j.ctrv.2025.102889_b0350","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ctrv.2025.102889_b0355","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102889_b0360","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102889_b0365","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102889_b0370","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102889_b0375","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/CAD.0000000000000814","article-title":"Tumour flare reaction in cancer treatments: a comprehensive literature review","volume":"30","author":"Taleb","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2025.102889_b0380","article-title":"Tumor flare reaction in a classic Hodgkin lymphoma patient treated with brentuximab vedotin and tislelizumab: a case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102889_b0385","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21571","article-title":"Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma","volume":"85","author":"Corazzelli","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102889_b0390","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102889_b0395","doi-asserted-by":"crossref","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. Jul 2022;170:256-284. doi:10.1016\/j.ejca.2022.04.018.","DOI":"10.1016\/j.ejca.2022.04.018"},{"issue":"13","key":"10.1016\/j.ctrv.2025.102889_b0400","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102889_b0405","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DDDT.S368954","article-title":"Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations","volume":"17","author":"Montazeri","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102889_b0410","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/ajd.13866","article-title":"A review of the cutaneous toxicities of tebentafusp-featuring two cases involving superficial bullous reactions","volume":"63","author":"Pham","year":"2022","journal-title":"Australas J Dermatol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102889_b0415","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label. phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102889_b0420","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","article-title":"International real-world study of DLL3 expression in patients with small cell lung cancer","volume":"147","author":"Rojo","year":"2020","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102889_b0425","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102889_b0430","unstructured":"FDA approves IMDELLTRATM (Tarlatamab-DLLE), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer. Amgen. Accessed July 7, 2024. https:\/\/www.amgen.com\/newsroom\/press-releases\/2024\/05\/fda-approves-imdelltra-tarlatamabdlle-the-first-and-only-tcell-engager-therapy-for-the-treatment-of-extensivestage-small-cell-lung-cancer."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:27:50Z","timestamp":1744190870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":86,"alternative-id":["S0305737225000118"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102889","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of bispecific T cell\u2013engaging antibody toxicity: A primer for emergency physicians","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102889"}}